Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

How I Treat Older Patients with Ph/BCR-ABL-Negative Acute Lymphoblastic Leukemia

Nicola Gökbuget, Björn Steffen

Blood blood.2023023156.

https://doi.org/10.1182/blood.2023023156

Published: 2024

Journal Articles

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, Renato Bassan

Blood (2024) 143 (19): 1891–1902.

https://doi.org/10.1182/blood.2023020794

Published: 2024

Includes: Supplemental data

Journal Articles

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Blood (2024) 143 (19): 1903–1930.

https://doi.org/10.1182/blood.2023023568

Published: 2024

Includes: Supplemental data

Journal Articles

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR :: ABL1 -positive ALL

Blood (2024) 143 (14): 1391–1398.

https://doi.org/10.1182/blood.2023021752

Published: 2024

Includes: Supplemental data

Journal Articles

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia

Blood (2023) 141 (13): 1640–1644.

https://doi.org/10.1182/blood.2022017249

Published: 2023

Includes: Supplemental data

Journal Articles

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi

Blood (2022) 140 (11): 1200–1228.

https://doi.org/10.1182/blood.2022015850

Published: 2022

Includes: Supplemental data

Journal Articles

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux, Christoph Faul, Helmut Diedrich, Max S. Topp, Monika Brüggemann, Heinz-August Horst, Violaine Havelange, Julia Stieglmaier, Hendrik Wessels, Vincent Haddad, Jonathan E. Benjamin, Gerhard Zugmaier, Dirk Nagorsen, Ralf C. Bargou

Blood (2018) 131 (14): 1522–1531.

https://doi.org/10.1182/blood-2017-08-798322

Published: 2018

Includes: Supplemental data

Journal Articles

Hematopoietic stem cell involvement in BCR-ABL1– positive ALL as a potential mechanism of resistance to blinatumomab therapy

Inga Nagel, Marius Bartels, Johannes Duell, Hans-Heinrich Oberg, Sandra Ussat, Henrike Bruckmueller, Oliver Ottmann, Heike Pfeifer, Heiko Trautmann, Nicola Gökbuget, Almuth Caliebe, Dieter Kabelitz, Michael Kneba, Heinz-August Horst, Dieter Hoelzer, Max S. Topp, Ingolf Cascorbi, Reiner Siebert, Monika Brüggemann

Blood (2017) 130 (18): 2027–2031.

https://doi.org/10.1182/blood-2017-05-782888

Published: 2017

Includes: Supplemental data

Journal Articles

Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase

Anjali S. Advani, MD, Elias J. Jabbour, MD, Matthias Stelljes, Daniel J. DeAngelo, MD PhD, Michaela Liedtke, MD, Wendy Stock, MD, Nicola Gökbuget, MD, Susan O'Brien, MD, Kongming Wang, PhD, Tao Wang, PhD, M. Luisa Paccagnella, PhD, Barbara Sleight, MD, Erik Vandendries, MD PhD, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 5188.

https://doi.org/10.1182/blood.V128.22.5188.5188

Published: 2016

Journal Articles

Multi-Genomics of Relapsed B-Cell Precursor Acute Lymphoblastic Leukemia Reveals Three Distinct Genetic Clusters Characterized By Different Alterations

Blood (2016) 128 (22): 453.

https://doi.org/10.1182/blood.V128.22.453.453

Published: 2016

Journal Articles

High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials

Blood (2016) 128 (22): 2803.

https://doi.org/10.1182/blood.V128.22.2803.2803

Published: 2016

Journal Articles

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

Blood (2016) 128 (6): 774–782.

https://doi.org/10.1182/blood-2016-02-700153

Published: 2016

Includes: Supplemental data

Journal Articles

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Gerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, Andreas Viardot, Matthias Stelljes, Svenja Neumann, Heinz-A. Horst, Reinhard Marks, Christoph Faul, Helmut Diedrich, Albrecht Reichle, Monika Brüggemann, Chris Holland, Margit Schmidt, Hermann Einsele, Ralf C. Bargou, Max S. Topp

Blood (2015) 126 (24): 2578–2584.

https://doi.org/10.1182/blood-2015-06-649111

Published: 2015

Includes: Supplemental data

Journal Articles

Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Nicola Gökbuget, MD, Hervé Dombret, MDPhD, Massimiliano Bonifacio, MD, Albrecht Reichle, MD, Carlos Graux, MDPhD, Christoph Faul, MD, Helmut Diedrich, MD, Max S. Topp, MD, Monika Brüggemann, MD, Heinz A. Horst, MD PhD, Julia Stieglmaier, PhD, Hendrik Wessels, MD, Vincent Haddad, MSc, Gerhard Zugmaier, MD, Dirk Nagorsen, MD, Ralf C Bargou, MD

Blood (2015) 126 (23): 680.

https://doi.org/10.1182/blood.V126.23.680.680

Published: 2015

Journal Articles

Non-Functional ("haploinsufficient"), but Not Dominant Negative Clonal IKZF1 Deletions Confer an Adverse Prognosis in Adult BCR-ABL -Negative Acute Lymphoblastic Leukemia

Benjamin Kobitzsch, Nicola Gökbuget, MD, Stefan Schwartz, MD, Richard Reinhardt, PhD, Monika Brueggemann, Andreas Viardot, MD, Ralph Wäsch, MD PhD, Michael Starck, MD, Eckhard Thiel, MD, Dieter Hoelzer, MD, Thomas Burmeister, MD

Blood (2015) 126 (23): 2617.

https://doi.org/10.1182/blood.V126.23.2617.2617

Published: 2015

Journal Articles

Genomic Profiling Reveals Gain of Mutations in Histone Methylation Regulators in Relapsed Adult B Cell Precursor ALL

Lorenz Bastian, Martin Neumann, MD, Nicola Gökbuget, MD, Cornelia Schlee, Jutta Ortiz Tanchez, Sebastian Vosberg, Alva Rani James, Michael P Schroeder, Stefan Schwartz, MD, Dieter Hoelzer, Alexander Graf, PhD, Stefan Krebs, PhD, Helmut Blum, PhD, Jochen Hecht, Monika Brüggemann, Philipp A. Greif, Claudia D. Baldus, MD PhD

Blood (2015) 126 (23): 2625.

https://doi.org/10.1182/blood.V126.23.2625.2625

Published: 2015

Journal Articles

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

Blood (2014) 124 (26): 3870–3879.

https://doi.org/10.1182/blood-2014-03-563627

Published: 2014

Includes: Supplemental data

Journal Articles

BCR-ABL1-like Acute Lymphoblastic Leukemia Is Associated with IKZF1 and JAK2 Alterations and inferior Outcome in Adults

Blood (2014) 124 (21): 3787.

https://doi.org/10.1182/blood.V124.21.3787.3787

Published: 2014

Journal Articles

Favorable Outcome in a Large Cohort of Prospectively Treated Adult Patients with T-Lymphoblastic Lymphoma (T-LBL) Despite Slowly Evolving Complete Remission Assessed By Conventional Radiography

Nicola Gökbuget, MD, Andrea Wolf, Matthias Stelljes, MD, Andreas Hüttmann, MD, Eike C. Buss, Andreas Viardot, Kalina Brandt, MD, Maike de Wit, MD, Norbert Frickhofen, MD, Maxim Kebenko, MD, Mustafa Kondakci, MD, Doris Kraemer, MD, Stefan Schwartz, MD, Hubert Serve, MD, Karsten Spiekermann, MD, Reingard Stuhlmann, MD, Albrecht Reichle, Dieter Hoelzer, MD

Blood (2014) 124 (21): 370.

https://doi.org/10.1182/blood.V124.21.370.370

Published: 2014

Journal Articles

FAT1 Expression and Mutation Status In Adult Acute Lymphoblastic Leukemia

Martin Neumann, MD, Marco Seehawer, MS, Cornelia Schlee, MS, Sebastian Vosberg, Sandra Heesch, MS, Eva von der Heide, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, PhD, Nicola Gökbuget, MD, Stefan Schwartz, MD, Dieter Hoelzer, MD, Philipp A Greif, MD, Claudia D. Baldus, MD, PhD

Blood (2013) 122 (21): 2564.

https://doi.org/10.1182/blood.V122.21.2564.2564

Published: 2013

NARROW

How I Treat Older Patients with Ph/BCR-ABL-Negative Acute Lymphoblastic Leukemia

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR :: ABL1 -positive ALL

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Hematopoietic stem cell involvement in BCR-ABL1– positive ALL as a potential mechanism of resistance to blinatumomab therapy

Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase

Multi-Genomics of Relapsed B-Cell Precursor Acute Lymphoblastic Leukemia Reveals Three Distinct Genetic Clusters Characterized By Different Alterations

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Non-Functional ("haploinsufficient"), but Not Dominant Negative Clonal IKZF1 Deletions Confer an Adverse Prognosis in Adult BCR-ABL -Negative Acute Lymphoblastic Leukemia

Genomic Profiling Reveals Gain of Mutations in Histone Methylation Regulators in Relapsed Adult B Cell Precursor ALL

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

BCR-ABL1-like Acute Lymphoblastic Leukemia Is Associated with IKZF1 and JAK2 Alterations and inferior Outcome in Adults

Favorable Outcome in a Large Cohort of Prospectively Treated Adult Patients with T-Lymphoblastic Lymphoma (T-LBL) Despite Slowly Evolving Complete Remission Assessed By Conventional Radiography

FAT1 Expression and Mutation Status In Adult Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only